leadf
logo-loader
viewChampignon Brands Inc.

Champignon Brands CEO Dr Roger McIntyre elected chairman of the board

Dr McIntyre is a professor of psychiatry and pharmacology at the University of Toronto and heads the Mood Disorders Unit at the University Health Network in Toronto

Champignon Brands Inc. - Champignon Brands Inc CEO Dr Roger McIntyre has been elected chairman of its board of directors
The company's dual mission is to help those suffering from mental health disorders in its own ketamine-based clinics and to develop the next generation of novel psychedelic treatments and delivery systems

Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) has announced that CEO Dr Roger McIntyre has been elected chairman of its board of directors.

A foremost international expert in depression and suicide, Dr McIntyre is a professor of psychiatry and pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto, and has appointments among scientific and clinical organizations across the US and Asia, the company said in a statement Monday

Dr McIntyre was appointed to the board on July 22 after assuming the role of CEO in May. 

READ: Champignon Brands to offer esketamine for depression at Ontario clinic

Champignon Brands said the CEO has set out a strategic direction for the business which includes a focus on "breakthrough treatments of depression" through the development of government-approved ketamine compounds and a network of treatment clinics. 

The company's dual mission is to help those suffering from mental health disorders in its own ketamine-based clinics and to develop the next generation of novel psychedelic treatments and delivery systems.

Champignon Brands said it continues to work with the British Columbia Securities Commission to address the ongoing continuous disclosure review and is confident that the review will be resolved soon.

In other company news, Bill Wilkerson, who was appointed to the board in May, has been elected vice-chair, bringing to the position extensive experience in business, government, and mental health.

Champignon, based in Vancouver, specializes in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness, and alternative medicine industries.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Champignon Brands Inc.

Price: 0.89 CAD

CSE:SHRM
Market: CSE
Market Cap: $70.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Champignon Brands Inc. named herein, including the promotion by the Company of Champignon Brands Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Champignon Brands charts course for success with acquisitions and a name change

Champignon Brands (CSE: SHRM- OTCQB: SHRMF) CEO Dr Roger McIntyre joined Steve Darling from Proactive Vancouver with news the company is changing its name to Apotheosis, which means the high point of development. McIntyre discusses the thinking behind the change, plus acquisitions and other...

on 22/6/20

2 min read